Beyond the Lipid Panel: Elevated Lp(a), Lifetime Risk and What the Evidence Says About Aspirin- Dr Ambar Bhatnagar

A reassuring lipid panel can still hide an inherited cardiovascular risk. Lipoprotein(a) [Lp(a)] escapes routine lipid testing (8), and a 2024 NHANES III analysis asked whether it could identify who may benefit from aspirin in primary prevention (1).

Who is the primary-prevention patient? A midlife adult with no known heart disease and, often, a reassuring lipid panel. In NHANES III, this meant 2,990 adults aged 40–70 years (median 50.2; 53.1% women) without established atherosclerotic cardiovascular disease (ASCVD). Cohort averages were BMI

27.7 kg/m², total cholesterol 214 mg/dL, HDL cholesterol 50 mg/dL, median triglycerides 127.7 mg/dL and systolic blood pressure 126 mmHg; 6.3% had diabetes and 23.6% were current smokers (1). About 1 in 6 (15.7%) had Lp(a) ≥50 mg/dL, the group in whom the aspirin association emerged (1).

Lp(a): An Inherited Cardiovascular Risk Factor Beyond the Routine Lipid Panel

Lp(a) concentrations are largely determined by variation in the LPA gene and stay relatively stable through adult life. Elevated Lp(a) is an independent ASCVD risk factor with genetic evidence of causality; risk rises progressively with concentration, and markedly elevated levels carry substantially greater lifetime risk (2,8). Roughly 20–30% of the general population has Lp(a) above 30 mg/dL; at ≥50 mg/dL, about one-fifth of people worldwide are affected, versus about one-quarter in Indian studies (2,4,5).

Because conventional lipids, lifestyle or clinical history cannot reliably predict elevated Lp(a), current ESC/EAS and ACC/AHA guidelines support measuring it at least once in adulthood to refine risk assessment and guide prevention (6,7).

The Hidden Multiplier: How Lp(a) Raises Cardiovascular Risk to Age 80

The European Atherosclerosis Society (EAS) Lp(a) Risk and Benefit Algorithm estimates how elevated Lp(a) may shift long-term cardiovascular risk beyond conventional risk factors (8).

Take an illustrative 50-year-old woman with the cohort's characteristics (BMI 27.7 kg/m²; total cholesterol 214 mg/dL, LDL cholesterol approximately 139 mg/dL, HDL cholesterol 50 mg/dL; systolic blood pressure 126 mmHg; no antihypertensive treatment, diabetes, smoking or family history of heart attack or stroke). Her estimated risk of heart attack or stroke by age 80 rises from 10.2% without Lp(a) to 13.1% when an Lp(a) of 50 mg/dL is included: an absolute increase of 2.9 percentage points, or about 28% in relative terms.

These are modelled estimates, not observed NHANES III event rates, but they show how adding Lp(a) can shift risk classification and preventive discussions (8).

Figure 1: EAS Lp(a) Risk and Benefit Algorithm, age 50–80

Beyond Cholesterol: Lp(a)'s Thrombotic Biology and the Rationale for Aspirin

Lp(a) has established atherogenic properties and potentially prothrombotic effects. Apolipoprotein(a) resembles plasminogen, raising the possibility of interference with fibrinolysis, and experimental studies implicate platelet activation via protease-activated receptor-1 (PAR-1) and CD36. Their clinical contribution remains uncertain (1,2,8).

This rationale justifies investigating antiplatelet therapy in elevated Lp(a), but mechanistic plausibility is not clinical benefit in primary prevention (1,2). Bleeding is the main constraint: in ASPREE, which enrolled adults aged 70 years or older without cardiovascular disease (an older population than NHANES III), major haemorrhage over a median of 4.7 years occurred in 3.8% on low-dose aspirin versus 2.8% on placebo (HR 1.38; 95% CI 1.18–1.62) (11). Decisions therefore need individualised assessment of absolute ASCVD risk, age, bleeding susceptibility and other clinical factors, not elevated Lp(a) alone (1,8).

Evidence in Numbers: Aspirin Use and ASCVD Mortality Across Lp(a) Levels

NHANES III participants were linked to National Death Index records over a median follow-up of 26 years. Regular aspirin use, defined as at least 30 doses in the preceding month, was reported by approximately 7% (1).

Among individuals with Lp(a) ≥50 mg/dL, ASCVD mortality was 1.2 per 1,000 person-years in regular aspirin users versus 3.9 in non-users (1).

After adjustment for demographics, cardiovascular risk factors and relevant medications, regular aspirin use was associated with a 52% lower hazard of ASCVD mortality in those with elevated Lp(a) (hazard ratio [HR] 0.48; 95% confidence interval [CI] 0.28–0.83), but not in those with Lp(a) below 50 mg/dL (HR 1.01; 95% CI 0.81–1.25); the interaction was significant (P=0.001) (1).

Figure 2: Regular Aspirin Use and ASCVD Mortality by Lp(a) Level

A sensitivity analysis defining regular use as at least 15 doses per month gave a consistent result in those with elevated Lp(a) (HR 0.43; 95% CI 0.26–0.72) (1).

Genetic subgroup analyses of two randomised trials offer supporting evidence. In the Women's Health Study, aspirin allocation was associated with fewer cardiovascular events among carriers of an LPA-associated variant. In ASPREE, the genetic analysis suggested a potentially favourable balance of events prevented against bleeding harm in selected subgroups, although these exploratory findings need confirmation (2,3).

These findings are observational and cannot show that aspirin reduced ASCVD mortality; bleeding outcomes were unavailable, so net clinical benefit could not be assessed (1).

From Evidence to Practice: Managing Lp(a)-Associated Risk

Identifying elevated Lp(a) lets clinicians refine risk assessment and intensify established preventive strategies, alongside one-time measurement and optimisation of modifiable risk factors (6–8).

Management should prioritise appropriate LDL-C lowering, blood pressure control, diabetes management and smoking cessation. Aspirin may warrant consideration in selected higher-risk adults, but decisions must weigh age, bleeding history, comorbidities, concomitant medications and patient preferences; the EAS consensus does not recommend aspirin solely because Lp(a) is elevated (8).

Targeted Lp(a)-lowering therapies, meanwhile, remain under investigation. In September 2026, topline results from the phase III Lp(a)HORIZON trial showed that pelacarsen lowered Lp(a) but did not meet its primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established cardiovascular disease; full results will be presented at an upcoming medical congress (9).

Key Messages

• Elevated Lp(a) is an inherited cardiovascular risk factor that conventional lipid assessment can overlook; measuring it at least once in adulthood sharpens lifetime ASCVD risk estimation and supports individualised prevention (6–8).
• In NHANES III, regular aspirin use was observationally associated with lower ASCVD mortality in individuals with Lp(a) ≥50 mg/dL. Given the observational design and the unresolved bleeding trade-off, this is not a recommendation for routine aspirin in everyone with elevated Lp(a) (1).
• Recognising Lp(a)-associated risk, optimising established preventive measures and tailoring aspirin decisions to overall cardiovascular and bleeding risk remain the evidence-supported approach.

This article is intended for healthcare professionals for scientific and educational purposes. The use of aspirin discussed here in individuals with elevated Lp(a) is investigational and is not an established or guideline-recommended indication; the observational findings cited do not establish causation or net clinical benefit. Prescribers should refer to the approved prescribing information of any product before prescribing.